Evidence map›Paper›PMID 24571259›Full record

ReviewBritish journal of haematology2014

LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma.

Chen Lossos, Soley Bayraktar, Elizabeth Weinzierl, Sheren F Younes, Peter J Hosein, Robert J Tibshirani, Jocelyn Sutton Posthumus, Lisa M DeAngelis, Jeffrey Raizer, David Schiff and 3 more

Open access · bronzeAbstract readMulticenter StudyReview
PubMed Full text at PMC Publisher
In one paragraph

Review in British journal of haematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2017
    Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Chen LossosDivision of Hematology-Oncology, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA.
Soley Bayraktar
Elizabeth Weinzierl
Sheren F Younes
Peter J Hosein
Robert J Tibshirani
Jocelyn Sutton Posthumus
Lisa M DeAngelis
Jeffrey Raizer
David Schiff
Lauren Abrey
Yasodha Natkunam
Izidore S Lossos
Stanford University · USMemorial Sloan Kettering Cancer Center · USSylvester Comprehensive Cancer Center · USUniversity of Miami · USUniversity of Virginia · USNorthwestern University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Significance and Function of HGAL in LymphomaR01CA109335 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LOSSOS, IZIDORE S · 2005 to 2013
$2.1M
Prognostic Models in Diffuse Large B-Cell LymphomaR01CA122105 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LOSSOS, IZIDORE S · 2007 to 2010
$1.3M
NCI NIH HHS CA109335NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA109335NCI NIH HHS R01 CA122105
6 · The paper itself

Abstract

Primary central nervous system lymphoma (PCNSL) is an aggressive sub-variant of non-Hodgkin lymphoma (NHL) with morphological similarities to diffuse large B-cell lymphoma (DLBCL). While methotrexate (MTX)-based therapies have improved patient survival, the disease remains incurable in most cases and its pathogenesis is poorly understood. We evaluated 69 cases of PCNSL for the expression of HGAL (also known as GCSAM), LMO2 and BCL6 - genes associated with DLBCL prognosis and pathobiology, and analysed their correlation to survival in 49 PCNSL patients receiving MTX-based therapy. We demonstrate that PCNSL expresses LMO2, HGAL(also known as GCSAM) and BCL6 proteins in 52%, 65% and 56% of tumours, respectively. BCL6 protein expression was associated with longer progression-free survival (P = 0·006) and overall survival (OS, P = 0·05), while expression of LMO2 protein was associated with longer OS (P = 0·027). Further research is needed to elucidate the function of BCL6 and LMO2 in PCNSL.

Indexed as

Adaptor Proteins, Signal TransducingAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCentral Nervous System NeoplasmsDNA-Binding ProteinsHumansKaplan-Meier EstimateLIM Domain ProteinsLymphoma, Non-HodgkinMethotrexateMiddle AgedNeoplasm ProteinsPrognosisAdaptor Proteins, Signal TransducingBCL6 protein, humanBiomarkers, TumorDNA-Binding ProteinsLIM Domain ProteinsLMO2 protein, humanMethotrexateNeoplasm ProteinsProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-6BCL6HGALLMO2PCNSLprognosis

Identifiers

PMID24571259
PMCPMC4123533
OpenAlexW1966020824

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.